TheEdgeResearch
Home / Stocks / GMDA

Gamida Cell Ltd. (GMDA)

NASDAQ Healthcare Biotechnology
$0.03 ▲ +0.00%
Market Cap
$4.3M
Sector
Healthcare
Industry
Biotechnology
Beta
1.03
52-Wk Range
—
CEO
Abigail L. Jenkins
Country
IL
Currency
USD

Gamida Cell Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Jerusalem, IL. The stock last traded at $0.03, up 0.00% on the session, giving a market capitalisation of $4.3M. On trailing twelve-month figures it carries a trailing P/E of -0.08, a net margin of -3531.2%. Its beta of 1.03 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.08
Price / Sales
2.43
Price / Book
-1.65
EV / EBITDA
-0.76
Gross margin
-95.0%
Operating margin
-4094.1%
Net margin
-3531.2%
Return on equity
—
Debt / equity
-28.13
Current ratio
2.16
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Market
Employees
143
IPO date
2018-10-26
Headquarters
Jerusalem, IL
About Gamida Cell Ltd.

Gamida Cell Ltd. operates as a clinical-stage biopharmaceutical firm, dedicated to pioneering cell therapies aimed at eradicating blood cancers and other severe hematological conditions. The company's leading investigational product, omidubicel—a specialized cell therapy—has successfully concluded its Phase III clinical evaluation for individuals afflicted with high-risk hematologic malignancies. Furthermore, it is currently undergoing Phase I/II trials for patients suffering from severe aplastic anemia. Another significant therapeutic candidate, GDA-201, an immunotherapy harnessing natural killer cells, is progressing through Phase I/II studies to address relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Beyond these, Gamida Cell is actively advancing a broader natural killer (NK) cell pipeline, which includes GDA-301, GDA-401, GDA-501, and GDA-601, with the ambition of treating both hematologic cancers and solid tumors. Founded in 1998, the company maintains its corporate headquarters in Jerusalem, Israel.

Comparable companies

Gamida Cell Ltd. is most often compared with the following Healthcare names:

APTOBCELCYTOGRTSHILSIDRANBRVFNEUPRVLPTNFA
More research on GMDA
GMDA technical analysis GMDA TheEdge Score Compare against peers
Open full interactive analysis & DCF →